Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Bagoly, Zsuzsa ^a   Sarkady, Ferenc ^a   Magyar, Tünde ^a   Kappelmayer, János ^a   Pongrácz, Endre ^b   Csiba, László ^a   Muszbek, László ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Szent Imre Hospital   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS EQUIPMENT; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN PHOSPHORYLATION; REFERENCE VALUE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION TEST;

ADENOSINE DIPHOSPHATE; ADULT; AGED; ALPROSTADIL; BLOOD PLATELETS; CELL ADHESION MOLECULES; CLINICAL LABORATORY TECHNIQUES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REPRODUCIBILITY OF RESULTS; STROKE; TICLOPIDINE;

EID: 84879771552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069417     Document Type: Article

References (34)

1. Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK, (2012) P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 33: 143-153. doi:10.1007/s11239-011-0667-5. PubMed: 22183178.
2. Nguyen TA, Diodati JG, Pharand C, (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45: 1157-1164. doi:10.1016/j.jacc.2005.01.034. PubMed: 15837243.
3. Huang B, Huang Y, Li Y, Yao H, Jing X, et al. (2012) Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res 43: 212-224. doi:10.1016/j.arcmed.2012.04.004. PubMed: 22564422.
4. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, et al. (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56: 919-933. doi:10.1016/j.jacc.2010.04.047. PubMed: 20828644.
5. Mallouk N, Labruyère C, Reny JL, Chapelle C, Piot M, et al. (2012) Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost 107: 494-506. doi:10.1160/TH11-03-0202. PubMed: 22273694.
6. Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F, (2012) High on treatment platelet reactivity. Heart Lung Circ 21: 12-21. doi:10.1016/j.hlc.2011.08.069. PubMed: 22000771.
7. Smock KJ, Saunders PJ, Rodgers GM, Johari V, (2011) Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Am J Hematol 86: 1032-1034. doi:10.1002/ajh.22112. PubMed: 21812020.
8. Shiraga M, Miyata S, Kato H, Kashiwagi H, Honda S, et al. (2005) Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 3: 2315-2323. doi:10.1111/j.1538-7836.2005.01554.x. PubMed: 16194207.
9. van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, et al. (2008) The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 19: 479-488. doi:10.1080/09537100802317918. PubMed: 18979359.
10. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, et al. (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3: 85-92. doi:10.1111/j.1538-7836.2004.01063.x. PubMed: 15634270.
11. Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, et al. (2008) Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline-third edition. Clinical and Laboratory Standards Institute Document C28-A3.
12. Gurbel PA, Tantry US, (2011) Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. Thromb Haemost 106: 265-271. doi:10.1160/TH11-03-0167. PubMed: 21713326.
13. Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, et al. (2010) Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 8: 482-488. doi:10.1111/j.1538-7836.2009.03733.x. PubMed: 20040042.
14. Cattaneo M, (2011) The clinical relevance of response variability to antiplatelet therapy. Hematology Am Soc Hematol Educ Programs, 2011(2011): 70-75. PubMed: 22160014.
15. Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK, (2012) P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 33: 143-153. doi:10.1007/s11239-011-0667-5. PubMed: 22183178.
16. Cattaneo M, (2012) Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost 10: 327-336. doi:10.1111/j.1538-7836.2011.04602.x. PubMed: 22221409.
17. Bouman HJ, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, et al. (2011) A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 9: 909-916. doi:10.1111/j.1538-7836.2011.04255.x. PubMed: 21382172.
18. Aradi D, Komócsi A, Price MJ, Cuisset T, Ari H, et al. (2012) Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol. PubMed: 22704866.
19. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, et al. (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5: 1199-1202. doi:10.1038/13522. PubMed: 10502826.
20. Jarvis GE, Humphries RG, Robertson MJ, Leff P, (2000) ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors. Br J Pharmacol 129: 275-282. doi:10.1038/sj.bjp.0703046. PubMed: 10694233.
21. Tentzeris I, Siller-Matula J, Farhan S, Jarai R, Wojta J, et al. (2011) Platelet function variability and non-genetic causes. Thromb Haemost 105 (Suppl 1):: S60-S66. doi:10.1160/THS11-01-0025. PubMed: 21491057.
22. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, et al. (2011) Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 32: 459-466. doi:10.1007/s11239-011-0611-8. PubMed: 21706290.
23. Müller I, Besta F, Schulz C, Massberg S, Schönig A, et al. (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89: 783-787. PubMed: 12719773.
24. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM, (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913. doi:10.1161/01.CIR.0000072771.11429.83. PubMed: 12796140.
25. Sollier Bal Dit, C, Berge N, Boval B, Dubar M, Drouet L (2010) Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 104: 571-581. doi:10.1160/TH09-11-0803. PubMed: 20664906.
26. Sollier Bal Dit, C, Berge N, Boval B, Hovsepian L, Drouet L (2009) Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 101: 116-122. PubMed: 19132197.
27. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, et al. (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303: 754-762. doi:10.1001/jama.2010.181. PubMed: 20179285.
28. Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, et al. (2010) Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Platelets 21: 563-570. doi:10.3109/09537104.2010.494742. PubMed: 20642320.
29. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, et al. (2009) Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 101: 333-339. PubMed: 19190818.
30. Tobin WO, Kinsella JA, Coughlan T, Collins DR, O'Neill D, et al. (2013) High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. Eur J Neurol 20: 344-352. doi:10.1111/j.1468-1331.2012.03861.x. PubMed: 22994699.
31. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, et al. (2008) A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 99: 215-222. PubMed: 18217157.
32. Aw D, Sharma JC, (2012) Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice? Postgrad Med J 88: 34-37. doi:10.1136/postgradmedj-2011-130100. PubMed: 22121248.
33. Topçuoglu MA, Arsava EM, Ay H, (2011) Antiplatelet resistance in stroke. Expert Rev Neurother 11: 251-263. doi:10.1586/ern.10.203. PubMed: 21306212.
34. Shulga O, Bornstein N, (2011) Antiplatelets in secondary stroke prevention. Front Neurol 2: 36. PubMed: 21772826.